COVID-19: Understanding What We Know After Five Years

Guillain-Barré Syndrome and Venous Thrombosis (9/10)
Researchers observed an increase in cases of Guillain-Barré syndrome (GBS) and cerebral venous thrombosis (CVT) following the first dose of the AstraZeneca vaccine.

Guillain-Barré syndrome typically causes progressive muscle weakness.

Cerebral venous thrombosis occurs when a blood clot forms in a vein in the brain, obstructing blood circulation.

French basketball player Victor Wembanyama previously suffered from a form of thrombosis, which forced him to end his season.

More Research Is Needed (10/10)
In addition, all vaccines showed an increased risk of myocarditis and pericarditis — inflammations of the heart muscle or its surrounding tissue — although these events remain rare.

“Other issues have been identified that require further research,” the journal notes.
Researchers emphasize that additional investigation is necessary to fully understand the relationship between vaccination and these adverse events.

Conclusion
COVID-19 vaccines were developed under urgent circumstances during a global health crisis.
After nearly five years of real-world data and scientific analysis, we now have a clearer — though still evolving — understanding of the possible side effects associated with these vaccines.